DE69838986D1 - Polypeptide, deren herstellung und verwendung - Google Patents

Polypeptide, deren herstellung und verwendung

Info

Publication number
DE69838986D1
DE69838986D1 DE69838986T DE69838986T DE69838986D1 DE 69838986 D1 DE69838986 D1 DE 69838986D1 DE 69838986 T DE69838986 T DE 69838986T DE 69838986 T DE69838986 T DE 69838986T DE 69838986 D1 DE69838986 D1 DE 69838986D1
Authority
DE
Germany
Prior art keywords
function
polypeptides
preparation
aids
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838986T
Other languages
English (en)
Other versions
DE69838986T2 (de
Inventor
Shuji Hinuma
Kazuhiko Tatemoto
Masaki Hosoya
Yugo Habata
Ryo Fujii
Chieko Kitada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of DE69838986D1 publication Critical patent/DE69838986D1/de
Application granted granted Critical
Publication of DE69838986T2 publication Critical patent/DE69838986T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69838986T 1997-12-24 1998-12-22 Polypeptide, deren herstellung und verwendung Expired - Lifetime DE69838986T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP35395597 1997-12-24
JP35395597 1997-12-24
JP3257798 1998-02-16
JP3257798 1998-02-16
JP22085398 1998-08-04
JP22085398 1998-08-04
JP27164598 1998-09-25
JP27164598 1998-09-25
PCT/JP1998/005805 WO1999033976A1 (en) 1997-12-24 1998-12-22 Polypeptide, their production and use

Publications (2)

Publication Number Publication Date
DE69838986D1 true DE69838986D1 (de) 2008-02-21
DE69838986T2 DE69838986T2 (de) 2009-01-08

Family

ID=27459639

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838986T Expired - Lifetime DE69838986T2 (de) 1997-12-24 1998-12-22 Polypeptide, deren herstellung und verwendung

Country Status (9)

Country Link
US (3) US6492324B1 (de)
EP (1) EP1040189B1 (de)
KR (1) KR20010033601A (de)
CN (1) CN1283228A (de)
AT (1) ATE383424T1 (de)
AU (1) AU1685499A (de)
CA (1) CA2313246A1 (de)
DE (1) DE69838986T2 (de)
WO (1) WO1999033976A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1062337B1 (de) * 1998-03-13 2011-11-09 Brown University Research Foundation Isoform des humanen n-artigen calciumkanals und dessen verwendungen
AU5759399A (en) * 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative
AU1797100A (en) * 1998-12-11 2000-07-03 Takeda Chemical Industries Ltd. Process for producing apelin
DE60119714T2 (de) * 2000-03-23 2006-09-07 Takeda Chemical Industries, Ltd. Peptidderivat
DE10138569A1 (de) * 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
WO2003063892A1 (fr) * 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Utilisation d'apeline
CA2512071A1 (en) 2002-12-30 2004-07-22 The Regents Of The University Of California Methods and apparatus for pathogen detection and analysis
US7342105B2 (en) 2003-02-28 2008-03-11 Takeda Chemcial Industries, Ltd. Antibody and use thereof
ATE471722T1 (de) * 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7947280B2 (en) * 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
WO2006019193A1 (ja) * 2004-08-20 2006-02-23 Takeda Pharmaceutical Company Limited 阻害剤・促進剤の用途
US20060045880A1 (en) * 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
WO2007072980A1 (ja) 2005-12-20 2007-06-28 Takeda Pharmaceutical Company Limited アペリンの新規用途
WO2007123233A1 (ja) 2006-04-25 2007-11-01 Kyushu University, National University Corporation 動脈硬化性疾患関連遺伝子、およびその利用
WO2009033739A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US8946382B2 (en) * 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
US9381229B2 (en) 2011-11-28 2016-07-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
KR20150127596A (ko) 2013-03-14 2015-11-17 리제너론 파아마슈티컬스, 인크. 아펠린 융합 단백질 및 이들의 용도
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3157942B1 (de) 2014-06-23 2020-06-17 Novartis AG Ortsspezifische proteinmodifikationen
EP3206707B1 (de) 2014-10-13 2020-12-02 University of Maryland, Baltimore Fc-ela-32 und deren verwendung zur behandlung von herzerkrankungen
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
US10426818B2 (en) * 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
EP3416688B1 (de) 2016-02-15 2022-08-17 INSERM - Institut National de la Santé et de la Recherche Médicale Apelin zur verwendung bei der behandlung von postoperativer kognitiver dysfunktion
EP3228630A1 (de) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Kombination eines apelin-antagonisten und angiogeneseinhibitor zur behandlung von krebs
CN108376608B (zh) * 2018-02-10 2020-11-06 青岛大学 一种磁性纳米粒子及其制备磁性固相载体的用途
CN110655577A (zh) * 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
CN109575117B (zh) * 2018-12-14 2021-09-21 昆明积大制药股份有限公司 [Pyr1]-apelin-13的制备方法
WO2024023034A1 (en) 2022-07-25 2024-02-01 Institut National de la Santé et de la Recherche Médicale Use of apelin for the treatment of lymphedema

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2128208C (en) * 1992-11-17 2004-01-06 Ronald Godiska Novel seven transmembrane receptors
WO1997011159A1 (en) * 1995-09-20 1997-03-27 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein

Also Published As

Publication number Publication date
US7410776B2 (en) 2008-08-12
US20090075334A1 (en) 2009-03-19
US20030092618A1 (en) 2003-05-15
EP1040189A1 (de) 2000-10-04
ATE383424T1 (de) 2008-01-15
WO1999033976A1 (en) 1999-07-08
US6492324B1 (en) 2002-12-10
CN1283228A (zh) 2001-02-07
CA2313246A1 (en) 1999-07-08
US7799533B2 (en) 2010-09-21
DE69838986T2 (de) 2009-01-08
EP1040189B1 (de) 2008-01-09
KR20010033601A (ko) 2001-04-25
AU1685499A (en) 1999-07-19

Similar Documents

Publication Publication Date Title
DE69838986D1 (de) Polypeptide, deren herstellung und verwendung
NO20014415D0 (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
DE3773057D1 (de) Vorrichtung zur kontrollierten abgabe von arzneimitteln, ihre zubereitung und verwendung.
DE59006880D1 (de) Gerät zur Herstellung von Formkörpern und Verwendung desselben zur Herstellung von Inlays, Onlays, und Kronen in der Zahnmedizin.
NO962088D0 (no) Preparat for in vivo-produksjon av terapeutiske produkter
TR199802789T2 (xx) Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
HK1065323A1 (en) Human dr4 antibodies and uses thereof
ATE100098T1 (de) Nukleoside, ihre herstellung und pharmazeutische zusammenstellungen.
SE9201930D0 (sv) Gastric antibacterial treatment
ATE74487T1 (de) Verfahren zur herstellung und verwendung fester, pflanzenwirksamer zusammensetzungen.
MC1884A1 (fr) Variants de l'hirudine,leur utilisation et leur preparation
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
DE3784046D1 (de) Pulverfoermige emulgiermittelzubereitung, ihre herstellung und verwendung.
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
DE50114335D1 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
DE69327693D1 (de) Interferon-Alpha/Beta bindendes Protein, seine Herstellung und seine enthaltende pharmazeutische Zusammensetzungen
DK1431391T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
DE69011465D1 (de) Verwendung von Human-ADF (=Adult T-cell leukemia-derived factor) zur Herstellung von Medikamenten.
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE3788888D1 (de) Perhydrothiazepin- und Perhydroazepinderivate, ihre Herstellung und ihre therapeutische Verwendung.
DE59104754D1 (de) Transparente, thermoplastische Polyetheresteramidimid-Elastomere sowie ihre Verwendung zur Herstellung von medizinischen Gebrauchsartikeln.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition